EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 4-Dec-2025 08:11 ET (4-Dec-2025 13:11 GMT/UTC)

New organ-on-a-chip platform allows the testing of cancer vaccine efficacy in aging populations

Terasaki Institute for Biomedical Innovation
Peer-Reviewed Publication

Dr. Vadim Jucaud’s lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates age-dependent immune responses, offering a more accurate testing bed for evaluating cancer vaccine performance in older adults, the population most affected by cancer and often overlooked in traditional preclinical testing.

Journal: Lab on a Chip
Funder: Terasaki Institute for Biomedical Innovation

Renuka Iyer, MD, named new Chief Medical Officer for National Comprehensive Cancer Network (NCCN)

National Comprehensive Cancer Network
Business Announcement

The National Comprehensive Cancer Network (NCCN)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care— announces the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization.

Pathway discovered to make the most common breast cancer tumor responsive to immunotherapy

IMIM (Hospital del Mar Medical Research Institute)
Peer-Reviewed Publication

A study from the Hospital del Mar Research Institute, published in The Journal of Clinical Investigation, indicates that the high expression of the estrogen receptor is the main factor preventing the most common type of breast cancer, luminal breast cancer, from responding to immunotherapy.

The high presence of the estrogen receptor sequesters the LCOR molecule, whose action on tumor cells is necessary to make tumors visible to the immune system. In experimental models, the researchers found that combining immunotherapy with endocrine therapy allows LCOR to function and the immune system to attack the tumor.

At the same time, they have generated a modified version of the LCOR molecule that sensitizes tumors to immunotherapy, including those with hormone receptors. The next goal is to study this molecule combined with immunotherapy in clinical trials.

Journal: Journal of Clinical Investigation

Australian-first imaging center will provide unprecedented detail on how cancers interact with their microenvironment

Garvan Institute of Medical Research
Business Announcement

Australian researchers will soon have an unprecedented ability to see how cancer cells interact with their microenvironment, thanks to a new imaging centre being established at the Garvan Institute of Medical Research. The ACRF MATRIX Centre – short for Mass spectrometry Analysis of Tumour Response In compleX microenvironments – will help scientists understand why some cancers resist treatment and spread through the body, with the overall aim of developing therapies which target both the cancer cells and the microenvironment around them.

Funder: ACRF

Global initiative for glycolipid metabolic health

KeAi Communications Co., Ltd.
Peer-Reviewed Publication

Glycolipid metabolic disorders, linked to cardiovascular diseases and cancer, are a major global health challenge. Current single-disease treatments remain unsatisfied in reducing long-term risks. In 2024, Professor Jiao Guo along with global experts launched the "Global Initiative for Glycolipid Metabolic Health" to enhance prevention through scientific research, public education, and integrated management systems.

Journal: Journal of Holistic Integrative Pharmacy

Scientists find cancer weak spot in backup DNA repair system

Scripps Research Institute
Peer-Reviewed Publication

The DNA inside our cells is constantly being damaged, and one of the worst kinds of damage is a double-strand break—when both sides of the DNA helix are cut at once. Healthy cells can normally fix these breaks using highly precise repair systems, but when those systems fail, cells sometimes resort to a less accurate backup method. Now, scientists at Scripps Research have discovered when and how this backup repair pathway gets activated, and how the process could be turned against cancer cells that rely on it to survive.

Breast density notification increases levels of confusion and anxiousness among women

University of Sydney
Peer-Reviewed Publication

New research by experts at the University of Sydney shows that breast density notification is leaving some women confused and anxious about their breast health. Breast density notification is being rolled out across Australia, but evidence suggests that women do not feel more informed by it. Between 25 and 40 percent of women have denser breast tissue which can make it harder for cancers to be detected through a mammogram.

Journal: BMJ
Funder: National Health and Medical Research Council

Telling women as part of mammography screening that they have dense breasts may have unintended effects

BMJ Group
Peer-Reviewed Publication

Recommendations introduced in Australia and being considered in the UK to tell women if they have dense breasts as part of their screening results may have unintended effects and increase demand on health services, finds a clinical trial designed to assess the real-world impact of notification, published by The BMJ today.

Journal: The BMJ
Funder: National Health and Medical Research Council, National Breast Cancer Foundation, Cancer Screening Unit, Department of Health, Queensland Government

Research reveals how disordered protein regions contribute to cancer-causing condensates

St. Jude Children's Research Hospital
Peer-Reviewed Publication

A machine learning-based resource developed at St. Jude Children’s Research Hospital predicts which intrinsically disordered regions can drive the formation of biomolecular condensates and links those proteins to RNA biology.

Journal: Science Advances

Researchers identify target to overcome treatment resistance in preclinical models of KRAS-mutant cancers

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance

Reducing RASH3D19 also reduced tumor growth and sensitized cancer cells to KRAS inhibitors

Combining RASH3D19 blockers with KRAS inhibitors improved outcomes in preclinical models

Journal: Nature Cell Biology

1
2
3